Merck Rival Summit Draws New Buy From Truist on Deal Prospects
Merck, Johnson & Johnson Share Losses Lead Dow's 180-Point Fall
The HPV vaccine for males has been approved in the country, with Merck being the first to enter the market!
Will the male market be a lifeline?
Major banks rating | Truist: The biopharmaceutical Industry needs more mergers and acquisitions to recover, lowering Merck's Target Price to $110.
Glonghui, January 8 | Truist Securities states that the biopharmaceutical Industry in 2024 is disappointing in terms of mergers and acquisitions; the Industry requires larger/more merger transactions to recover. Truist downgraded Merck's rating from "Buy" to "Hold," with the Target Price lowered from $130 to $110. (Glonghui)
Global Equities Roundup: Market Talk
Merck's Near-Term Growth Path Uncertain -- Market Talk